Hormonal
Tirzepatide produces significantly greater weight loss than semaglutide in patients with type 2 diabetes, with a mean difference of -4.84 kg favoring tirzepatide.
If you have Type 2 Diabetes and are choosing between Tirzepatide and Semaglutide for weight loss, Tirzepatide is likely to produce greater weight loss (approx. 4.8 kg more on average). Both drugs share similar gastrointestinal side effect profiles, which are generally manageable. The choice may depend on individual response, tolerability, and cost/insurance coverage, but Tirzepatide shows superior efficacy in head-to-head comparisons.
The meta-analysis supports these findings with a mean difference of −4.84 kg (95% CI: −6.21 to −3.47), favouring tirzepatide.
Why this rating
Meta-analysis of 4 studies with large sample size (28,827 patients), though heterogeneity (I2=78.3%) is noted.
Source
Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta‐Analysis of Direct Comparative Studies
Jimmy Wen et al. · Endocrinology Diabetes & Metabolism · 2025
DOI 10.1002/edm2.70045
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →